GSA Capital Partners LLP Makes New Investment in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

GSA Capital Partners LLP bought a new position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 93,032 shares of the company’s stock, valued at approximately $84,000.

Several other institutional investors have also modified their holdings of LCTX. Rhumbline Advisers grew its position in Lineage Cell Therapeutics by 15.1% in the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after acquiring an additional 17,411 shares during the period. Defender Capital LLC. lifted its stake in shares of Lineage Cell Therapeutics by 0.6% in the 3rd quarter. Defender Capital LLC. now owns 5,002,198 shares of the company’s stock valued at $4,528,000 after purchasing an additional 29,223 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Lineage Cell Therapeutics during the 3rd quarter worth $46,000. Renaissance Technologies LLC increased its position in shares of Lineage Cell Therapeutics by 10.0% during the 2nd quarter. Renaissance Technologies LLC now owns 583,622 shares of the company’s stock worth $582,000 after purchasing an additional 53,022 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Lineage Cell Therapeutics in the 2nd quarter valued at about $61,000. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN LCTX opened at $0.57 on Tuesday. The stock has a market capitalization of $108.56 million, a price-to-earnings ratio of -4.79 and a beta of 1.28. Lineage Cell Therapeutics, Inc. has a 1-year low of $0.50 and a 1-year high of $1.61.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. D. Boral Capital dropped their price target on shares of Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Craig Hallum began coverage on shares of Lineage Cell Therapeutics in a report on Tuesday, August 20th. They issued a “buy” rating and a $4.00 target price for the company.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.